3 articles
Novo Nordisk shut its internal cell therapy unit and licensed the asset to AI-native platform Cellular Intelligence, even as Q1 2026 earnings and its stock climbed. The move tracks a broader pharma shift toward outside AI drug-discovery specialists, part of an NVIDIA-backed wave that includes BioNeMo, MindWalk's HYFT/ReefIQ, Boltz Lab, Owkin, Natera, Basecamp Research and Edison Scientific.
Paradigm Health's Study Conduct platform has gone live simultaneously hosting Phase 1b and Phase 2 clinical trials for Amgen and AstraZeneca. Operational failures—data loss, EHR outages, or algorithmic misclassification—could delay or invalidate trial data for both companies. Risk assessors rate the failure scenario as catastrophic severity with medium likelihood, exposing both pharma giants to timeline disruptions and regulatory complications.
Pfizer has confirmed plans to enter the lucrative GLP-1 obesity drug market by 2028, following its acquisition of Metsera. The move positions the pharmaceutical giant to compete directly with Novo Nordisk and Eli Lilly in a sector projected to exceed $100 billion in annual revenue. For investors, the timeline and strategic rationale carry significant implications for PFE stock valuation.